Hefei Haishen Biopharmaceutical

Hefei Haishen Biopharmaceutical is an innovative biotechnology company based in Hefei, China, specializing in the development of advanced immune cell therapies. Established in 2021, the company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and TCR-T technologies to treat various forms of cancer, including hematological malignancies and solid tumors. Their research emphasizes the development of off-the-shelf universal CAR-T (UCAR-T) products designed to enhance accessibility and reduce treatment costs for patients. Haishen Biopharmaceutical operates a state-of-the-art R&D facility in the Hefei High-tech Zone, leveraging local clinical resources and government support. The company's mission is to translate cutting-edge immunology research into breakthrough clinical applications for unmet medical needs in oncology.